This article is more than 5 years old. Information may no longer be current.
Moffitt Cancer Center names malignant hematology department chair
Click Here to Manage Email Alerts
Jeffrey E. Lancet, MD, has been named chair and program leader for the department of malignant hematology at Moffitt Cancer Center.
Lancet, who has served as interim chair since last summer, has recognized for his research using novel therapies for patients with acute leukemias.
“Dr. Lancet’s training and experience reflect excellence in clinical practice and clinical research associated with acute leukemias and myelodysplastic syndromes,” G. Douglas Letson, MD, executive vice president of clinical affairs and physician-in-chief at Moffitt Cancer Center, said in a press release. “He has consistently provided strong leadership within Moffitt Cancer Center, serving in many important roles, including chief of medicine services.”
Lancet received the NCI-ASCO Clinical Investigator Team Leadership Award in 2010. He recently was appointed to the FDA’s Oncologic Drugs Advisory Committee.
“I am thrilled, honored and grateful to assume the role of chair and program leader of the malignant hematology department,” Lancet said in the press release. “Our program at Moffitt is already one of the finest in the nation for patient care and research in blood cancers, and I plan to build upon this success in both the clinical and scientific arenas with a variety of new initiatives that ultimately will benefit our patients, some of which include renowned faculty/scientist recruitments, multidisciplinary clinics for the best patient care, and instituting more cutting-edge clinical trials led by Moffitt doctors.”